Risk of recalls and sales suspensions involving medical equipment and pharmaceuticals
First written in FY2016. 21 of 23 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2026: 11 of 57 companies on the "Worse" side.
125 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「The group strives to maintain business relationships with diverse suppliers so that it can supply substitute products even if specific products become unavailable for sale.」
The company continues to identify the possibility that product recalls or sales suspensions could affect performance, and indicates that alternative supply from diverse suppliers is a response measure. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2022-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2020RestatedAnnual report
「Accordingly, the Group endeavors to maintain business relationships with diverse suppliers so that it can supply substitute products even if a particular product becomes unavailable for sale.」
The company continues to cover products manufactured and marketed by エクソーラメディカル and products procured externally in its disclosure on recall and sales suspension risks, and also refers to alternative supply from diverse suppliers. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2019RestatedAnnual report
「If products manufactured and marketed by 株式会社エクソーラメディカル are recalled or their sale is suspended because of defects or other issues, this may affect the Group's performance.」
The company continues to identify the possibility that recalls or sales suspensions involving products manufactured and marketed by エクソーラメディカル or products procured externally could affect performance. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2018RestatedAnnual report
「If products manufactured and marketed by 株式会社エクソーラメディカル are recalled or their sale is suspended because of defects or other issues, this may affect the Group's performance.」
The company continues to identify the possibility that recalls or sales suspensions involving products manufactured and marketed by エクソーラメディカル or products procured from outside the group could affect performance. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2017WorsenedAnnual report
「If products manufactured and marketed by 株式会社エクソーラメディカル are recalled or their sale is suspended because of defects or other issues, this may affect the Group's performance.」
The company states that, in addition to the risk of recalls and sales suspensions for products procured from external manufacturers, products manufactured and marketed by エクソーラメディカル could also be similarly affected, expanding the scope of the risk. - FY2017-Q3RestatedAnnual report
「There were no occurrences of matters relating to the business, financial conditions or other items described in this quarterly report that could have a material impact on investors' decisions during the cumulative third quarter, and no significant changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of recalls and sales suspensions for medical devices and pharmaceuticals. - FY2016First statedAnnual report
「Although the group, which is not a manufacturer or marketer, is not directly responsible for these obligations, if products it sells are recalled or their sale is suspended due to defects or other reasons, this could indirectly affect the performance of the group as the distributor.」
The company indicates that recalls or sales suspensions resulting from defects or other issues with products it handles could affect performance as a distributor.